Application of serum GSDME in diagnosis, curative effect monitoring and prognosis evaluation of B lymphocytic leukemia

Abstract

The invention discloses application of serum GSDME in diagnosis, curative effect monitoring and prognosis evaluation of B lymphocytic leukemia. The invention provides application of serum GSDME in preparation of a kit for diagnosing B lymphocytic leukemia and/or monitoring the curative effect of B lymphocytic leukemia and/or evaluating the prognosis of B lymphocytic leukemia. The kit contains a reagent for detecting the expression level of GSDME in serum and/or plasma. By establishing an immunological detection method of serum (plasma) GSDME, what is verified is that the serum (plasma) GSDME has good diagnostic specificity and sensitivity to B lymphocytic leukemia, and what is verified is that serum GSDME has important clinical application value in treatment effect monitoring and prognosis evaluation of B lymphocytic leukemia. On the working basis, a corresponding serum GSDME detection kit can be directly transformed and developed to diagnose B lymphocytic leukemia, monitor the curative effect of B lymphocytic leukemia and evaluate the prognosis of B lymphocytic leukemia.

Description

technical field [0001] The invention relates to the technical field of B lymphocytic leukemia curative effect monitoring and prognosis evaluation, in particular to the use of serum GSDME in B lymphocytic leukemia diagnosis, curative effect monitoring and prognosis evaluation. Background technique [0002] Lymphpocytic Leukemia (LL) is divided into acute lymphoma (ALL) and chronic lymphocytic leukemia (CLL), including many subtypes. ALL is one of the most common childhood malignancies and the leading cause of childhood cancer-related deaths. CLL is a chronic B-lymphocyte clonal proliferation, a highly heterogeneous disease, and it usually occurs in adults. [0003] At present, the curative effect monitoring and prognostic evaluation of lymphocytic leukemia mainly divide clinical curative effect into complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD) by evaluating parameters such as tumor burden and hematopoietic system function....

AI Technical Summary

Problems solved by technology

This has the following disadvantages: ① If the cancer tissue is not obtained by surgical resection or biopsy, such as conservative treatment such as radiotherapy and chemotherapy, relevant detection will not be possible

②Immunohistochemical staining, RT-PCR, and gene chip detection are all empirical qualitative, or indirect semi-quantitative indicators through relevant image processing software, and cannot be accurately observed, compared, and judged quantitatively

Although a real-time RT-PCR method can be established to accurately quantify the GSDME gene, it is still limited by the above-mentioned sample acquisition; and, affected by various protein translation regulation factors, the amount of mRNA cannot completely and accurately represent the amount of GSDME

③ The above-mentioned immunohistochemical staining, PCR, and gene chip technologies can be completed in large research hospitals, but they are difficult to implement in many clinical hospitals, especially primary hospitals, which will inevitably limit their wide application and development.

Images